Novavax, Inc. has grown revenue −36% a year over three years and −19% a year over five. Revenue growth, 3-year annual rate: −36% (Biotechnology median +17%). Revenue growth, 5-year rate: −19%, growth has slowed since the five-year average. Years of annual history on file: 17, FY2009 to FY2025, as filed.

NVAXNovavax, Inc.

Healthcare

$12.74+46% 1Y

$12.74

$6.2252 weeks$12.74

Latest close: a new 52-week highOct 9, 2026what changed →

Is it growing?

Watch

Growth is fading: revenue shrinking (−62% year on year) and operating margin narrowing (−40.9 points).

2 to watch, 1 without data

Revenue trend−62% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: −19% a year.

Margin direction−40.9 points operating

Trailing-twelve-month operating margin, -87.7% now against -46.9% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is NVAX growing?

Novavax, Inc. has grown revenue −36% a year over three years and −19% a year over five.

−36%

Revenue growth, 3-year annual rate · Biotechnology median +17% · shrinking · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: −19%
Revenue growth, 5-year rate · −36% over three · growth has slowed since the five-year average
Years of annual history on file: 17
Years of annual history on file · FY2009 to FY2025, as filed

Details›